Table 4 SUCRA values and rankings produced based on all trials included in [29]
Treatment | Outcome | |||||||
|---|---|---|---|---|---|---|---|---|
Clear/nearly clear | Mean change in DLQI | PASI 75 | Withdrawal due to adverse events | |||||
SUCRA | Rank | SUCRA | Rank | SUCRA | Rank | SUCRA | Rank | |
Ixekizumab | 0.99 | 1 | 0.70 | 3 | 0.96 | 1 | 0.14 | 7 |
Secukinumab | 0.85 | 2 | 0.85 | 1 | 0.79 | 3 | 0.80 | 3 |
Infliximab | 0.67 | 3 | 0.80 | 2 | 0.81 | 2 | 0.04 | 8 |
Ustekinumab | 0.60 | 4 | 0.70 | 4 | 0.52 | 4 | 0.82 | 1 |
Adalimumab | 0.46 | 5 | 0.51 | 5 | 0.49 | 5 | 0.81 | 2 |
Etanercept | 0.28 | 6 | 0.31 | 6 | 0.28 | 6 | 0.46 | 6 |
Methotrexate | 0.15 | 7 | 0.15 | 7 | 0.15 | 7 | 0.47 | 4 |
Placebo | 0.00 | 8 | 0.00 | 8 | 0.00 | 8 | 0.47 | 5 |